Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years

Similar Items

• Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
  od: Schwarz, Tino F., i dr.
  Izdano: (2017)
• Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
  od: Schwarz, T, i dr.
  Izdano: (2015)
• Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study
  od: Romanowski, Barbara, i dr.
  Izdano: (2011)
• Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
  od: Romanowski, Barbara, i dr.
  Izdano: (2015)
• A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
  od: Schwarz, Tino F., i dr.
  Izdano: (2019)